Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Bridges

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Investigative Ophthalmology & Visual Science|November 10, 2021
Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma ModelJessica V Kaczmarek, Carley M Bogan, Janene M Pierce, et al.
Journal of Medicinal Chemistry|October 30, 2013
Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|December 15, 2012
Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe moleculeBruce J Melancon, Michael S Poslusney, Patrick R Gentry, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 4, 2013
Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanismThomas M Bridges, Jerri M Rook, Meredith J Noetzel, et al.
Molecular Pharmacology|May 2, 2009
A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learningDouglas J Sheffler, Richard Williams, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2019
Discovery of a novel 3,4-dimethylcinnoline carboxamide M<sub>4</sub> positive allosteric modulator (PAM) chemotype via scaffold hoppingKayla J Temple, Julie L Engers, Madeline F Long, et al.
ACS Medicinal Chemistry Letters|May 14, 2025
Discovery of ONO-TR-772 (VU6018042): A Highly Selective and CNS Penetrant TREK Inhibitor <i>in Vivo</i> Tool CompoundMotoyuki Tanaka, Takahiro Mori, Gakuji Hashimoto, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2011
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071Evan P Lebois, Gregory J Digby, Douglas J Sheffler, et al.
ACS Medicinal Chemistry Letters|August 14, 2024
Discovery of VU6008677: A Structurally Distinct Tricyclic M<sub>4</sub> Positive Allosteric Modulator with Improved CYP450 ProfileRory A Capstick, Sean R Bollinger, Julie L Engers, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2021
Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M<sub>4</sub> muscarinic acetylcholine receptorAaron M Bender, Trever R Carter, Matthew Spock, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Investigative Ophthalmology & Visual Science|November 10, 2021
Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma ModelJessica V Kaczmarek, Carley M Bogan, Janene M Pierce, et al.
Journal of Medicinal Chemistry|October 30, 2013
Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|December 15, 2012
Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe moleculeBruce J Melancon, Michael S Poslusney, Patrick R Gentry, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 4, 2013
Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanismThomas M Bridges, Jerri M Rook, Meredith J Noetzel, et al.
Molecular Pharmacology|May 2, 2009
A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learningDouglas J Sheffler, Richard Williams, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2019
Discovery of a novel 3,4-dimethylcinnoline carboxamide M<sub>4</sub> positive allosteric modulator (PAM) chemotype via scaffold hoppingKayla J Temple, Julie L Engers, Madeline F Long, et al.
ACS Medicinal Chemistry Letters|May 14, 2025
Discovery of ONO-TR-772 (VU6018042): A Highly Selective and CNS Penetrant TREK Inhibitor <i>in Vivo</i> Tool CompoundMotoyuki Tanaka, Takahiro Mori, Gakuji Hashimoto, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2011
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071Evan P Lebois, Gregory J Digby, Douglas J Sheffler, et al.
ACS Medicinal Chemistry Letters|August 14, 2024
Discovery of VU6008677: A Structurally Distinct Tricyclic M<sub>4</sub> Positive Allosteric Modulator with Improved CYP450 ProfileRory A Capstick, Sean R Bollinger, Julie L Engers, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2021
Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M<sub>4</sub> muscarinic acetylcholine receptorAaron M Bender, Trever R Carter, Matthew Spock, et al.
Pageof 11